Stavudine extended release (once-daily, Bristol-Myers Squibb) for the treatment of HIV/AIDS

Bibliography

• Dybul M, Fauci AS, Bartlett JG, et al. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents: recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Recomm Rep 2002;51:1-55
   PubMedGoogle Scholar
• Huang P, Farquhar D, Plunkett W. Selective action of 2′,3′- didehydro-2′,3′-dideoxythymidine triphosphate on human immuno deficiency virus reverse transcriptase and human DNA polymerases. J Biol Chem 1992;267:1817-22
   Google Scholar
• Squires KE, Gulick R, Tebas P, et al. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). AIDS 2000;14(11):1591-600
   PubMed Web of Science ®Google Scholar
• Cohen C, Elion R, Green S, et al. Sustiva (efavirenz) is highly effective and well tolerated in combination with the nucleosides stavudine and lamivudine (study DMP 266-043). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto, Ontario, Canada; 2000; poster 538
   Google Scholar
• Zerit (stavudine). Bristol-Myers Squibb Co., Princeton, NJ USA; Available from: http://www.bms.com/medicines/data/ [Last accessed 16 December 2012]
   Google Scholar
• Hurst M, Noble S. Stavudine: an update of its use in the treatment of HIV infection. Drugs 1999;58(5):919-49
   PubMed Web of Science ®Google Scholar
• Summary of the European public assessment report (EPAR) for Zerit. London; 1995-2012. Available from: http://www.ema.europa.eu/findmedicine/humanmedicines/europeanpublicassessmentreports [Last accessed 7 December 2012]
   Google Scholar
• Weller IV, Williams IG. ABC of AIDS. Antiretroviral drugs. BMJ 2001;322(7299):1410-12
   PubMed Web of Science ®Google Scholar
• Dieterich DT. Long-term complications of nucleoside reverse transcriptase inhibitor therapy. AIDS Read 2003;13:176-87
   PubMedGoogle Scholar
• Brinkman K, Smeitink JA, Romijn JA, et al. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999;354:1112-15
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2011. Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescent [Last accessed 7 December 2012]
   Google Scholar
• Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral Treatment of Adult HIV Infection. 2010 Recommendations of the International AIDS Society–USA Panel. JAMA 2010;304(3):321-33
   PubMed Web of Science ®Google Scholar
• European AIDS Clinical Society. Clinical management and treatment of HIV infected adults in Europe. Paris; 2012. Available from: http://www.europeanaidsclinicalsociety.org [Last accessed 7 December 2012]
   Google Scholar
• Documento de consenso de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antiretroviral en adultos infectados por el virus de la inmunodeficiencia humana. Panel de expertos de Gesida y Plan Nacional sobre el Sida. Enferm Infecc Microbiol Clin 2012;30:e1-89
   Google Scholar
• WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach (2006 Revision). WHO, Geneva; 2006. Available from: http://www.who.int/hiv/pub/guidelines/adult/en/index.html [Last accessed 15 December 2012]
   Google Scholar
• WHO. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. WHO, Geneva; 2009. Available from: http://www.who.int/hiv/pub/arv/rapid_advice_art.pdf [Last accessed 15 December 2012]
   Google Scholar
• Antiretroviral therapy for HIV infection in adults and adolescents Recommendations for a public health approach 2010 revision. Available from: http://www.who.int/hiv/pub/arv/adult2010/en/index.html [Last accessed 15 December 2012]
   Google Scholar
• WHO, UNAIDS and UNICEF. Towards universal access: scaling up of priority HIV/AIDS interventions in the health sector: Progress report. 2009. Available from: http://www.who.int/hiv/pub/2009progressreport/en/ [Last accessed 15 December 2012]
   Google Scholar
• Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral naive patients: a 3-year randomized trial. JAMA 2004;292(2):191-201
   PubMed Web of Science ®Google Scholar
• Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006;354(3):251-60
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
   PubMed Web of Science ®Google Scholar
• Zerit XR (Stavudine) Extended-Release Capsules. New drug approval. FDA/Center for Drug Evaluation and Research, US; 2002. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021453_s000_ZeritTOC.cfm [Last accessed 15 December 2012]
   Google Scholar
• FDA approval of three generic stavudine formulations. Available from: http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm121560.htm [Last accessed 15 December 2012]
   Google Scholar
• Saravanakumar M, Venkateswaramurthy N, Dhachinamoorthi D, et al. Extended release matrix tablets of Stavudine: Formulation and in vitro evaluation. Asian J Pharm 2010;4:219-23
   Google Scholar
• Padala NR, Reddy CS, Krishnaveni B, et al. Stavudine loaded microcapsules using various cellulose polymers: preparatin and in-vitro evaluation. Int J Pharm Sci Nanotechnol 2009;2:551-6
   Google Scholar
• Balzarini J, Herdewijn P, De Clercq E. Differential patterns of intracellular metabolism of 2,3-didehydro-2,3-dideoxythymidine and 3-azido-2,3-dideoxythymidine, two potent antihuman immunodeficiency virus compounds. J Biol Chem 1989;264:6127-33
   PubMed Web of Science ®Google Scholar
• Perno C-F, Yarchoan R, Cooney DA, et al. Replication of human immunodeficiency virus in monocytes. Ganulocyte/macrophage colony-stimulating factors (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3′-azido-2′3′-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine. J Exp Med 1989;169:933-51
   PubMed Web of Science ®Google Scholar
• Sørensen AM, Nielsen C, Mathiesen LR, et al. Evaluation of the combination effect of different antiviral compounds against HIV in vitro. Scand J Infect Dis 1993;25:365-71
   PubMed Web of Science ®Google Scholar
• Deminie CA, Bechtold CM, Stock D, et al. Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication. Antimicrob Agents Chemother 1996;40(6):1346-51
   PubMedGoogle Scholar
• Merrill DP, Moonis M, Chou T-C, et al. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency type 1 replication in vitro. J Infect Dis 1996;173:355-64
   PubMed Web of Science ®Google Scholar
• Deminie CA, Bechtold CM, Riccardi K, et al. Clinical HIV-1 isolates remain sensitive to stavudine following prolonged therapy. AIDS 1998;12(1):110-12
   PubMedGoogle Scholar
• Lin P-F, Gonzalez CJ, Griffith B, et al. Stavudine resistance: an update on susceptibility following prolonged therapy. Antiretroviral Ther 1999;4(1):7-20
   Google Scholar
• Larder BA, Bloor S, Kemp SD, et al. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrob Agents Chemother 1999;43(8):1961-7
   PubMed Web of Science ®Google Scholar
• Loveday C, Devereux H, Huckett L, et al. High prevalence of multiple drug resistance mutations in a UK HIV/AIDS patient population. AIDS 1999;13:627-8
   PubMedGoogle Scholar
• Coakley EP, Gillis JM, Hammer SM. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS 2000;14:F9-F15
   Google Scholar
• Pellegrin I, Izopet J, Reynes J, et al. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. AIDS 1999;13:1705-9
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Gazzard BG. Differing reverse transcriptase mutation patterns in individuals experiencing viral rebound on first-line regimens with stavudine/didanosine and stavudine/lamivudine. AIDS 2001;15:799-800
   PubMedGoogle Scholar
• Kaul S, Argawala S, Hess H, et al. Relative bioavailability of stavudine (d4t) extended-release (XR) formulation after coadministation with a high-fat meal in healthy subjects [poster no. TuPeB4555]. XIV International AIDS Conference; 7-12 July 2002; Barcelona
   Google Scholar
• Kaul S, Agarwala S, Hess H, et al. Stavudine extended release (XR*): single-dose, dose-proportionality study following oral administration in healthy subjects. Poster Exhibition: The XIV International AIDS Conference; Abstract no. TuPeB4555
   Google Scholar
• Kaul S, Bassi K, Damle B, et al. Stavudine Extended-Release Formulation (D4T XR) and Tenofovir Disoproxil Fumarate (TDF): Lack of a Pharmacokinetic (PK) Drug Interaction. 11th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2004; San Francisco, CA; Poster L30
   Google Scholar
• Kaul S, Swaminathan A, Behr D, et al. Single- and Multiple-Dose Pharmacokinetics (PK) of Stavudine (d4T) from an Extended-Release (XR) Formulation in Asymptomatic HIV-Infected Subjects. 9th Conference on Retroviruses and Opportunistic Infections; 24-28 February 2002, Seattle, WA; Poster 429-W
   Google Scholar
• Kaul S, Damle B, Gale J, et al. Pharmacokinetics (PK) of Stavudine (d4T) Extended Release (XR*) Formulation Compared with Stavudine Immediate Release (IR) Formulation as Part of Potent Antiretroviral Combination Therapy. 9th Conference on Retroviruses and Opportunistic Infections; 24-28 February 2002; Seattle, WA; Poster 430-W
   Google Scholar
• Stavudine Extended Release. Clinical report synopsis for protocol AI455-096. Bristol-Myers Squibb Co., 2001. Available from: http://ctr.bms.com/pdf//AI455096ST.pdf [Last accessed 17 December 2012]
   Google Scholar
• Montaner J, Baril J-G, DeJesus J, et al. Evaluation of the safety and antiviral activity of stavudine extended-release (ER) formulation as compared to stavudine immediate-release (IR). 8th European Conference on Clinical Aspects and Treatment of HIV-Infection; 2001. Athens; abstract no. LB/04
   Google Scholar
• Stavudine Extended Release. Clinical report synopsis for protocol AI455-099. Bristol-Myers Squibb Co., 2002. Available from: http://ctr.bms.com/pdf//AI455099ST.pdf [Last accessed 17 December 2012]
   Google Scholar
• Baril JG, Pollard RB, Raffi F, et al. Stavudine extended/prolonged release (XR/PRC) vs stavudine immediate release (IR) in combination with lamivudine and efavirenz: 48 week efficacy and safety. XIV International AIDS Conference; 2002. Barcelona; poster LbPeB9014
   Google Scholar
• Stavudine Extended Release. Clinical report synopsis for protocol AI455-110. Bristol-Myers Squibb Co., 2002. Available from: http://ctr.bms.com/pdf//AI455110ST.pdf [Last accessed 17 December 2012]
   Google Scholar
• Brett-Smith H, Reynolds L, Bessen L, et al. Analysis of Stavudine Extended-Release/Prolonged Release Capsules (XR/PRC) as Compared to Stavudine Immediate-Release (IR): Efficacy and Safety. 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003. Chicago; poster H843
   Google Scholar
• Yong Yang Y, Wilder-Smith A, Panchalingam A, et al. Changes in Body Fat Measured by DEXA in Patients Taking Different Formulations of Stavudine. HIV Clin Trials 2005;6(6):337-43
   PubMedGoogle Scholar
• Stavudine Extended Release. Clinical report synopsis for protocol AI455-131. Bristol-Myers Squibb Co., 2006. Available from: http://ctr.bms.com/pdf//AI455131.pdf [Last accessed 17 December 2012]
   Google Scholar
• Jayaweera D, DeJesus E, Nguyen KL, et al. Virologic suppression, treatment adherence, and improved quality of life on a once-daily efavirenz-based regimen in treatment-Naive HIV-1–infected patients over 96 weeks. HIV Clin Trials 2009;10(6):375-84
   PubMed Web of Science ®Google Scholar
• Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009;23(9):1109-18
   PubMed Web of Science ®Google Scholar
• Flexter C, Tierney C, Gross R, et al. Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS Clinical Trials Group (ACTG) A5073, a 48-Week randomized controlled trial. Clin Infect Dis 2010;50:1041-52
   PubMedGoogle Scholar
• Malan DR, Krantz E, David N, et al. Efficacy and safety of atazanavir, with or without ritonavir, as part of once daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr 2008;47:161-7
   PubMed Web of Science ®Google Scholar
• Stavudine Extended Release. Clinical report synopsis for protocol AI455-135. Bristol-Myers Squibb Co., 2006. Available from: http://ctr.bms.com/pdf//AI455135.pdf [Last accessed 17 December 2012]
   Google Scholar
• Boyle B, Jayaweera D, Witt MD, et al. Randomization to Once-Daily Stavudine Extended Release/Lamivudine/Efavirenz Versus a More Frequent Regimen Improves Adherence While Maintaining Viral Suppression. HIV Clin Trials 2008;9(3):164-76
   PubMed Web of Science ®Google Scholar